The firm has also begun an initiative to reduce and deliver sustainable revenue growth for 2019 to compensate for commercial challenges in the US market.
The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
Run by the daughter of a renowned genetic oncologist, CancerIQ is expanding and raising money as it rolls out its testing management and clinical decision support technology.
The investment bank called Genomic Health a leader in diagnostic testing and said Invitae will benefit from growth trends in the genetic testing sector.
There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.
The company said its test is the first biomarker-based diagnostic for IBD that predicts long-term disease outcome in Crohn's disease and ulcerative colitis.
The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.
Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.
A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.
Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.
In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.